Indication
Precursor B-Lymphoblastic Lymphoma Recurrent
4 clinical trials
10 products
2 drugs
Clinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Sub-protocol B Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Product
DasatinibProduct
VenetoclaxProduct
DexamethasoneDrug
cyclophosphamideProduct
CytarabineProduct
Intrathecal ChemotherapyClinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol C Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2030-10-01
Product
RuxolitinibDrug
lenalidomideProduct
Intrathecal chemotherapyClinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Not yet recruiting, Estimated PCD: 2029-10-01
Product
DecitabineProduct
NavitoclaxClinical trial
International Proof of Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory HEMatological Malignancies in Children, Subprotocol D: Trametinib + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesStatus: Recruiting, Estimated PCD: 2029-04-01
Product
Trametinib